FDA Approves TNKase for Acute Ischemic Stroke
THURSDAY, March 6, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a ...
GlobalData on MSN6d
Genentech wins FDA approval for second stroke treatment
Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.
Contract Pharma6d
Genentech’s TNKase Approved by FDA for Treatment of Strokes
The FDA has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in ...
Medscape6d
FDA Okays Tenecteplase for Acute Ischemic Stroke
Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the ...
PMLive5d
Roche’s Genentech granted FDA approval for TNKase in acute ischaemic stroke
Roche’s Genentech unit has received approval from the US Food and Drug Administration (FDA) for TNKase (tenecteplase) in ...
News-Medical.Net on MSN6d
FDA approves Genentech’s TNKase® in acute ischemic stroke in adults
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase® (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment ...
Medical Dialogues5d
FDA Approves Tenecteplase as First Stroke Drug in Nearly 30 Years
The US Food and Drug Administration has approved Tenecteplase as first FDA-approved stroke medication in nearly three decades ...
EMS13d
FDA approves clot-dissolving agent for treatment of acute ischemic stroke
TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...
News Medical6d
FDA approves Genentech’s TNKase® in acute ischemic stroke in adults
This approval of TNKase marks Genentech’s second approval for stroke, reinforcing the company's long-standing dedication to advancing stroke care as the developer of the only two FDA-approved ...
Endovascular Today6d
Genentech’s TNKase Approved by FDA to Treat Acute Ischemic Stroke in Adults
Genentech, a member of the Roche Group, announced that the FDA has approved the company’s TNKase (tenecteplase) thrombolytic ...
TCTMD6d
FDA Approves Tenecteplase for Acute Ischemic Stroke
The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.